Status:
RECRUITING
Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes
Lead Sponsor:
University of Cincinnati
Conditions:
Hypoglycemia
Type1diabetes
Eligibility:
All Genders
18-45 years
Phase:
NA
Brief Summary
Iatrogenic hypoglycemia is still considered to be the number one barrier to effective glycemic control in patients with type 1 diabetes (T1D). In a previous study, it was observed in people without di...
Detailed Description
Because patients with type 1 diabetes (T1D) are required to estimate and administer their own insulin requirements, they frequently overestimate their needs. This often leads to debilitating insulin-i...
Eligibility Criteria
Inclusion
- males and females of any race or ethnicity
- non-obese (BMI \< or = to 30)
- have a diagnosis of type 1 diabetes
- C-peptide negative
Exclusion
- pregnant women
- cigarette smoking
- Taking inflammation-targeting steroids (e.g., prednisone).
- Taking medications targeting adrenergic signaling (e.g., beta-blockers, bronchodilators).
- Hematocrit less than 33%.
- Presence of HIV or hepatitis (due to their deleterious effects on the liver).
- The presence of cardiovascular or peripheral vascular disease.
- The presence of neuropathy, retinopathy or nephropathy.
- A detection of the presence of any other disease or condition by one of the study doctors, that would be expected to confound the responses to insulin-induced hypoglycemia or make participation in the study dangerous to the individual.
Key Trial Info
Start Date :
October 10 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT05973799
Start Date
October 10 2019
End Date
December 31 2024
Last Update
September 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Cincinnati
Cincinnati, Ohio, United States, 45267-0547